CHARLOTTE, N.C. — In a Healio video exclusive, David T. Rubin, MD, FACG, reported guselkumab induced greater improvement across key outcomes compared with placebo among patients with moderate to severe ulcerative colitis.
Specifically, patients treated with guselkumab (Tremfya, Janssen) in the QUASAR phase 2b induction study demonstrated a greater clinical response at week 12 vs. placebo regardless of prior inadequate response or intolerance to advanced therapy (with: 50.5% vs. 25.5%; without: 70.3% vs. 29.6%). Further results showed similar effects across endoscopic and histologic